



Abram, S. G. F., Judge, A., Beard, D. J., & Price, A. J. (2019). Rates of adverse outcomes and revision surgery following anterior cruciate ligament (ACL) reconstruction: a study of 104,255 procedures using the national hospital episodes database for England, UK. *American Journal of Sports Medicine*, 2533-2542. https://doi.org/10.1177%2F0363546519861393

Peer reviewed version

License (if available): Other

Link to published version (if available): 10.1177%2F0363546519861393

Link to publication record in Explore Bristol Research PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via SAGE Publications at https://journals.sagepub.com/doi/full/10.1177/0363546519861393?url\_ver=Z39.88-2003&rfr\_id=ori:rid:crossref.org&rfr\_dat=cr\_pub%3dpubmed . Please refer to any applicable terms of use of the publisher.

# **University of Bristol - Explore Bristol Research** General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms

1	Rates of adverse outcomes and revision surgery following anterior cruciate ligament (ACL)
2	reconstruction: a study of 110,945 procedures using the national hospital episodes database for
3	England, UK
4	
5	S.G.F. Abram <sup>1</sup> , A. Judge <sup>1,2</sup> , D.J. Beard <sup>1</sup> , A.J. Price <sup>1</sup>
6	
7	Author addresses:
8	<sup>1</sup> Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
9	<sup>2</sup> Musculoskeletal Research Unit, NIHR Biomedical Research Unit, University of Bristol
10	
11	Author titles:
12	SA: NIHR Doctoral Research Fellow
13	AJ: Professor of Translational Statistics
14	DB: Professor of Musculoskeletal Sciences
15	AP: Professor of Orthopaedics
16	
17	Corresponding author:
18	Simon Abram
19	simon.abram@ndorms.ox.ac.uk
20	T: +44 1865 223425
21	NDORMS, University of Oxford, Botnar Research Centre, Windmill Road, Oxford OX3 7LD.

### 23 ABSTRACT

24

#### **25 BACKGROUND**

- 26 Following ACL injury, ACL reconstruction is an elective procedure and therefore an understanding of the
- 27 attributable risk from undergoing ACL reconstruction is necessary for patients to make a fully informed
- 28 treatment decision.
- 29 PURPOSE
- 30 To determine the absolute risk of adverse outcomes including reoperation following ACL reconstruction with
- 31 comparison, where possible, to the rate of adverse events reported in the general population.

### 32 STUDY DESIGN

33 Cohort study

### 34 METHODS

- 35 National hospital data on all ACL reconstructions performed in England between April 1, 1997 and March 31,
- 36 2017 were analysed. Revision cases, bilateral procedures within 6 months, and cases with concurrent cartilage
- 37 or multiple ligament surgery were excluded. The primary outcome was the occurrence of at least one serious
- 38 complication (myocardial infarction, stroke, pulmonary embolism, infection requiring surgery, fasciotomy,
- 39 neurovascular injury, or death) within 90-days. Additionally, 5-year rates of revision ACL reconstruction,
- 40 contralateral reconstruction, and meniscal surgery were investigated.

## 41 **RESULTS**

- 42 133,270 ACL reconstructions were performed of which 104,255 were eligible for analysis. Within 90 days,
- 43 serious complications occurred in 675 (0.65%; 95% confidence interval [CI] 0.60-0.70), including 494
- 44 reoperations for infection (0.47%; 95% CI 0.43-0.52) and 129 pulmonary embolisms (0.12%; 95% CI 0.10-
- 45 0.15). Of 54,275 patients with at least 5 years follow-up, 1746 (3.22%; 95% CI 3.07-3.37) underwent revision
- 46 ACL reconstruction in the same knee, 1553 contralateral ACL reconstruction (2.86%; 95% CI 2.72-3.01), and
- 47 340 (0.63%; 0.56-0.70) subsequent meniscal surgery. The overall risk of serious complications fell over time
- 48 (adjusted odds ratio [OR] 0.96 per year; 95% CI 0.95-0.98) however older patients (adjusted OR 1.11 per 5-
- 49 years; 95% CI 1.07-1.16) and patients with a greater modified Charlson comorbidity index (adjusted OR 2.41
- 50 per 10-units; 95% CI 1.65-3.51) were are higher risk. For every 850 (95% CI 720-1039) ACL reconstructions

51	done, one pulmonary embolism could be provoked. For every 213 (95% CI 195-233), one native knee joint
52	infection could be provoked.
53	CONCLUSION
54	The overall risk of adverse events following ACL reconstruction is low, however some rare but serious
55	complications, including infection or pulmonary embolism, may occur. Around 3% of patients undergo a
56	further same side or opposite side ACL reconstruction within five years. These data will inform shared
57	decision making between clinicians and patients considering their treatment options.
58	
59	What is known about this subject
60	• Before this study, several systematic reviews have attempted to estimate the risk of adverse events
61	after ACL reconstruction however the findings have been limited by small numbers of studies, small
62	number of patients, non-representative data sources, and concerns about incomplete data capture.
63	• For infection rates, a systematic review of level 2 studies published in 2017 reported a 0.43% deep
64	infection rate (58/13401; 95% CI 0.32 to 0.56). For pulmonary embolism, a systematic review of 47
65	included studies published in 2016 reported a rate of 0.14% (1/704; 95% CI 0.00 to 0.79). A rate of
66	revision ACL reconstruction of 3.59% (587/16336; 95% CI 3.31 to 3.89) was reported from a large
67	military health database series in 2016. A systematic review published in 2015 previously estimated a
68	12.5% (335/2682) risk of contralateral ACL injury.
69	
70	What this study adds to existing knowledge
71	• ACL reconstruction was associated with a 0.65% risk of serious complications within 90 days
72	(pulmonary embolism, infection requiring surgery, myocardial infarction, stroke, fasciotomy,
73	neurovascular injury, death).
74	• Using comparative general population data, it was determined that for every 850 fewer ACL
75	reconstructions performed, one pulmonary embolism and four native knee joint infections could be
76	provoked.
77	• Within 5-years, 3.2% patients require revision ACL reconstruction in the same knee, 0.63% undergo
78	meniscal surgery in the same knee, and 2.9% undergo ACL reconstruction in the opposite knee.

- Women are at lower risk of revision surgery and meniscal surgery but not opposite side
  reconstruction, in comparison to men.
- Although the risk of adverse events after ACL reconstruction is greater than after arthroscopic partial
   meniscectomy, the overall risk from this type of surgery remains low.
- Nevertheless, as ACL reconstruction may be an avoidable intervention for many people following
- 84 ACL injury, this new understanding of risk and reoperation rates is crucial for patients to be able to
- 85 make an informed treatment decision.
- 86

# **INTRODUCTION**

89	The incidence of anterior cruciate ligament (ACL) injury in the population is approximately 0.03%
90	per year, rising to over 3% in studies of certain professional athletes. <sup>26</sup> Reconstruction of the ACL is
91	frequently recommended due to functional impairment and concerns about the development of
92	meniscal or articular cartilage damage from recurrent instability of the knee. <sup>15,35</sup> The population rate
93	of ACL reconstruction ranges from approximately 8 to 52/100,000 people between countries; <sup>5,26</sup> in
94	England, the intervention rate was 24/100,000 in 2016-17. <sup>2</sup>
95	
96	In 2010, a clinical trial indicated that for many patients with an ACL injury, a strategy of
97	rehabilitation with optional delayed ACL reconstruction may avoid the need for surgery. <sup>16</sup> Other
98	groups, however, continue to advocate early reconstruction due the risks of cartilage and meniscal
99	damage from recurrent knee instability. <sup>11,14,16,19,25</sup> As ACL reconstruction is an elective procedure,
100	besides the anticipated benefits of undergoing the procedure, it is crucially important for patients and
101	clinicians to have knowledge of the specific risks. <sup>6</sup> Before this study, several studies have attempted
102	to estimate the risk of adverse events after ACL reconstruction. <sup>4,13,21,22,24,32–34</sup> The findings, however,
103	have generally been limited by small numbers of studies, small number of patients, non-
104	representative data sources, and concerns about incomplete data capture.
105	
106	The purpose of this study was to determine the risks of adverse outcomes following anterior cruciate
107	ligament reconstruction within 90-days of surgery, with comparison, where possible, to the rate of
108	adverse events reported in the general population. The secondary aim was to examine the risk of
109	subsequent ipsilateral and contralateral ACL reconstruction within 5-years.
110	

112 METHODS

#### 113

114 Data source

115 National Hospital Episode Statistics (HES) data was obtained from NHS Digital (application DARS-116 NIC-68703) and linked with the Office for National Statistics (ONS) mortality dataset. HES contains 117 a record of all patient attendances at NHS hospitals in England, covering episodes of care delivered 118 in treatment centres (including those in the independent sectors) funded by the NHS, episodes of care 119 in England where patients are resident outside of England, and privately funded patients treated within NHS England hospitals.<sup>28</sup> The information recorded in the HES database includes patient 120 121 demographic and residence data, primary and secondary diagnoses including comorbidities, and all procedures undertaken. The ONS mortality dataset contains national death certificate data, 122 irrespective of whether the death occurred in hospital or in the community. 123

124

### 125 Procedures

126 All HES records between 1 April 1997 and 31 March 2017 were extracted for patients undergoing 127 ACL reconstruction. Episodes were identified from the Classification of Surgical Operations and Procedures (OPCS-4) codes in the procedure fields within the HES data (W742 [excluding repair or 128 synthetic graft procedures W841, W842, W723, W724]).<sup>29</sup> Simultaneous or staged (within 6 months) 129 bilateral cases were excluded along with cases with concurrent articular cartilage or multiple 130 ligament surgery. Per patient, per side, only the first (primary) ACL procedure was included as an 131 132 index procedure. For each patient identified as undergoing an index ACL reconstruction, all the 133 patient's prior and subsequent hospital episodes were identified for the entire data extraction period. 134 Subsequent revision procedures in the same patient were not eligible for analysis as index procedures 135 but were analysed as reoperation outcomes (see Outcomes, below). Cases missing essential data 136 (age, sex, procedure date, procedure laterality) were excluded from the study. Cases missing non-137 essential data (index of multiple deprivation, ethnicity, rurality) were included except for analyses 138 adjusting for these specific variables.

140 <u>Outcomes</u>

141 Complications were identified by a review of a combination of the twenty International Statistical 142 Classification of Diseases and Related Health Problems (ICD-10) diagnosis fields per hospital episode and twenty-four OPCS operation fields per episode.<sup>29,39</sup> Complications identified from the 143 144 ICD-10 diagnosis fields were as follows: pulmonary embolism (PE), myocardial infarction, stroke, 145 lower respiratory tract infection, acute kidney injury, urinary tract infection, and neurovascular 146 injury. Complications identified from the OPCS operation codes were confirmed to match with the laterality (left versus right) of the index procedure using the OPCS laterality codes. The procedure-147 148 based complications were as follows: joint infection, fasciotomy, general reoperation (any surgical procedure performed in the same knee within 90 days), revision ACL reconstruction, meniscal 149 surgery, contralateral ACL reconstruction. Mortality data was extracted from the ONS mortality 150 151 fields. The primary outcome was the occurrence of at least one serious complication within 90-days 152 of an index ACL reconstruction. A serious complication was defined as either myocardial infarction, 153 stroke, pulmonary embolism, infection requiring surgery (open or arthroscopic irrigation and lavage 154 or debridement [excluding haemarthrosis]), fasciotomy, neurovascular injury, or death. The rate of each individual complication was then evaluated secondarily, with each complication counted 155 156 whether in isolation of in combination with other adverse outcomes. The secondary outcomes were revision ACL reconstruction procedures, subsequent meniscal surgery procedures in the same knee, 157 158 and contralateral knee ACL reconstruction procedures within 5-years.

159

160 <u>Statistical analysis</u>

161 Stata v15.1 (StataCorp, College Station, Texas, USA) was used to perform all analysis. Descriptive 162 statistics were used to report demographic data. Complication rates were reported with confidence 163 intervals corresponding to the proportion of the study sample. Logistic regression methods were used 164 to first calculate the unadjusted odds of each complication occurring within 90-days by age, sex,

165 index of multiple deprivation (quintile derived from regional factors in England including average

166 income, employment, education, housing, and crime; 1=least deprived area, 5=most deprived),<sup>30</sup> ethnicity, modified Charlson comorbidity index (Summary Hospital-level Mortality Indicator 167 Specification; derived with a maximum 5-year ICD-10 diagnosis code lookback period),<sup>7,20,41</sup> year of 168 169 treatment, ethnicity, and rurality. The odds ratios were then adjusted including all these variables in 170 the same statistical model. Cox proportional hazards modelling, adjusted in the same manner, was 171 used to identify associations with same side revision ACL reconstruction, contralateral ACL reconstruction, and same side meniscal surgery. Long-term rates of revision ACL reconstruction 172 were also assessed using a mortality adjusted Kaplan-Meier survival analysis (not undergoing 173 174 revision surgery).

175

176 In order to guide patients and clinicians regarding the relative risk of undergoing the procedure, age-

177 sex matched general population study data was reviewed where available in published data.

178 Population and adverse event numbers were extracted from the ONS national mortality report and

179 from publications reporting population rates of myocardial infarction, pulmonary embolus, stroke,

180 and septic arthritis respectively.<sup>10,12,17,36,38</sup> Annualised rates were adjusted directly to estimate 90-day

complication rates. The relative risk (risk ratio) of adverse events was calculated, where possible, by
comparing the adverse event rate in an age-sex matched sample of patients in the general population.
The number needed to harm (NNH) was calculated from the risk difference between the study cohort

and the general population data (attributable risk).

185

186 Role of the funding source

187 The sponsors of the study had no role in the design or conduct of the study. All authors take

188 responsibility for the contents of the study and the decision to proceed to publication.

### 189 **RESULTS**



- 191 Between 1 April 1997 and 31 March 2017, 133 270 ACL reconstructions (124 489 patients) were
- 192 identified of which 104 255 (102 309 patients) were included (Figure 1). The mean age of the case
- 193 cohort was 29.2 years (SD 9.68) and 23 435 (22.5%) were performed in female patients (Table 1).
- 194 The majority of patients had no record of comorbidities (modified Charlson index zero; 90.65%),
- 195 were of white ethnicity (75.62%), and from urban regions (79.97%) (Table 1). For five-year follow-
- 196 up ipsilateral ACL and meniscal surgery and contralateral ACL reconstruction, data was available
- 197 for 54,275 procedures (Table 2).
- 198

## 199 Figure 1: Case selection



- 215 \* Same side or contralateral surgical procedures (not mutually exclusive). Other procedures included knee arthroplasty, fusion,
- *interposition*.

# **TABLE 1: Demographics**

	n	%
All procedures		
Total	104 255	100%
Sex		
Male	80820	77.52% (77.27, 77.77)
Female	23435	22.48% (22.23, 22.73)
Age group (years)		
<20	15357	14.73% (14.52, 14.95)
20-39	72331	69.38% (69.10, 69.66)
40-59	16069	15.41% (15.19, 15.63)
60-79	475	0.46% (0.42, 0.50)
80+	23	0.02% (0.01, 0.03)
Charlson index		
0	94503	90.65% (90.47, 90.82)
1 - 15	9711	9.31% (9.14, 9.49)
16 - 30	39	0.04% (0.03, 0.05)
31 - 50	2	-0.00% (0.00, 0.01)
IMD		
1	21761	20.87% (20.63, 21.12)
2	20853	20.00% (19.76, 20.25)
3	20902	20.05% (19.81, 20.29)
4	20173	19.35% (19.11, 19.59)
5	18860	18.09% (17.86, 18.33)
Missing	1706	
Rurality		
Urban	83376	79.97% (79.73, 80.22)
Rural	20064	19.25% (19.01, 19.49)
Missing	815	
Ethnicity		
White	78839	75.62% (75.36, 75.88)
Asian	4658	4.47% (4.34, 4.60)
Black	2025	1.94% (1.86, 2.03)
Mixed	1245	1.19% (1.13, 1.26)
Other	1821	1.75% (1.67, 1.83)
Missing	15667	

221	The rates of adverse medical and surgical outcomes within 90-days, and ligamentous or meniscal
222	reoperation within 5-years, are summarised in Table 2. Overall, 0.97% underwent any reoperation
223	with 90-days (1013/104255; 95% CI 0.91 to 1.03) and 0.65% developed a serious complication
224	(675/104255; 95% CI 0.60 to 0.70) including a rate of 0.47% reoperations for presumed deep
225	infection (494/104255; 95% CI 0.43 to 0.52). The rate of pulmonary embolism was 0.12%
226	(129/104255; 95% CI 0.10 to 0.15), of neurovascular injury was 0.02% (19/104255; 95% CI 0.01 to
227	0.03), and of fasciotomy was 0.02% (17/104255; 95% CI 0.01 to 0.03). Within 5-years, 3.22%
228	(1746/54275; 95% CI 3.07 to 3.37) underwent a revision ACL reconstruction in the same knee,
229	2.86% (1553/54275; 95% CI 2.72 to 3.01) underwent ACL reconstruction to the opposite knee, and
230	0.63% (340/54275; 95% CI 0.56 to 0.70) underwent subsequent meniscal surgery in the same knee.
231	The longer-term rates of revision ACL reconstruction are summarised in the mortality adjusted
232	Kaplan-Meier chart, Figure 2, estimating revision rates out to 15-years by age group. Younger
233	patients were at greater risk of revision as shown (Figure 2, Table 4).

235	TABLE 2: Adverse outcome	s within 90-days a	and reoperation rates	within 5-years
			_	

	n	% (95% CI)
90-day adverse outcomes (n=104 255)		
Any re-operation <sup>‡</sup>	1013	0.97% (0.91, 1.03)
Serious complication †	675	0.65% (0.60, 0.70)
Infection*	494	0.47% (0.43, 0.52)
Lower respiratory tract infection	102	0.10% (0.08, 0.12)
Urinary tract infection	44	0.04% (0.03, 0.06)
Pulmonary embolism	129	0.12% (0.10, 0.15)
Myocardial infarction	4	< 0.01% (0.00, 0.01)
Mortality	14	0.01% (0.01, 0.02)
Stroke	2	< 0.01% (0.00, 0.01)
Acute kidney injury	13	0.01% (0.01, 0.02)
Neurovascular injury	19	0.02% (0.01, 0.03)
Fasciotomy	17	0.02% (0.01, 0.03)
Fatal pulmonary embolus	0	0.00% (0.00, 0.00)

5-year reoperation (n = 54 275)						
Revision ACLr	1746	3.22% (3.07, 3.37)				
Subsequent contralateral ACLr	1553	2.86% (2.72, 3.01)				
Meniscal surgery	340	0.63% (0.56, 0.70)				

*†* = At least one serious complication within 90 days, defined as either pulmonary embolism, myocardial infarction, stroke, infection

238 requiring surgery, fasciotomy, neurovascular injury, or death; \* = Infection requiring surgery (open or arthroscopic lavage and

*irrigation or debridement of wound or joint);*  $\ddagger = Any procedure performed in the same knee (e.g. washout, meniscal repair, repeat$ 

240 meniscectomy, chondroplasty, ligamentous surgery, fasciotomy); ACLr = ACL reconstruction

## 242 Figure 2: Long-term survival curve (not undergoing subsequent revision ACL reconstruction)





Patient factors associated with adverse outcomes within 90-days are summarised in Table 3. Female
patients were at lower odds of serious complications and infection; the overall odds of serious
complications and of infection fell slightly over time (Table 3). Older age groups (under 20-years vs.

- 20-39-years vs. 40-59-years) were at greater risk of serious complications and pulmonary embolism
  as were patients with a greater modified Charlson comorbidity index (Table 3). Index of multiple
  deprivation and rurality did not affect the odds of complications. Patients of black ethnicity were
  found to be at greater odds of serious complications (adjusted OR 1.61; 95% CI 1.03 to 2.52) mainly
  due to greater odds of infection in comparison to patients in White ethnicity groups (adjusted OR
  1.88; 95% CI 1.16 to 3.05). The adjusted odds of serious complications by each patient factor
  (including patient age) is shown graphically in the forest plot, Figure 3.
- 256

## 257 TABLE 3: Unadjusted and adjusted odds<sup>‡</sup> of serious complication, pulmonary embolism, infection

	Serious complication †		Pulmonary embolism		Infection*	
	(90 days)		(90 days)		(90 (	lays)
	Crude OR	Adjusted OR	Crude OR	Adjusted OR	Crude OR	Adjusted OR
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
Sex						
Male	1.00	1.00	1.00	1.00	1.00	1.00
Female	0.63 (0.51, 0.77)	0.61 (0.49, 0.77)	0.96 (0.63, 1.45)	0.91 (0.58, 1.41)	0.49 (0.38, 0.64)	0.48 (0.36, 0.65)
Age group						
<20	0.61 (0.47, 0.79)	0.60 (0.45, 0.80)	0.35 (0.15, 0.81)	0.42 (0.18, 0.98)	0.65 (0.48, 0.87)	0.64 (0.47, 0.88)
20-39	1.00	1.00	1.00	1.00	1.00	1.00
40-59	1.20 (0.98, 1.46)	1.26 (1.02, 1.56)	2.25 (1.54, 3.30)	2.50 (1.66, 3.76)	0.88 (0.68, 1.13)	0.90 (0.68, 1.18)
60-79	2.25 (1.06, 4.77)	1.94 (0.84, 4.45)	5.74 (1.81, 18.24)	5.32 (1.58, 17.93)	0.82 (0.20, 3.32)	0.45 (0.06, 3.22)
80+	6.83 (0.92, 50.79)	7.63 (1.01, 57.56)	/	-	-	-
Year						
Per year	0.98 (0.96, 0.99)	0.96 (0.95, 0.98)	0.97 (0.94, 1.01)	0.97 (0.93, 1.01)	0.98 (0.96, 1.00)	0.97 (0.94, 0.99)
Modified Charlso	on comorbidity index					
Per unit	1.11 (1.07, 1.14)	1.10 (1.05, 1.14)	1.16 (1.10, 1.23)	1.11 (1.04, 1.19)	1.07 (1.02, 1.12)	1.08 (1.03, 1.14)
Index of multiple	e deprivation (quintile	e)				
1 = least	1.00	1.00	1.00	1.00	1.00	1.00
2	1.08 (0.86, 1.36)	1.05 (0.82, 1.34)	0.73 (0.43, 1.24)	0.62 (0.35, 1.09)	1.16 (0.88, 1.52)	1.18 (0.89, 1.58)
3	0.95 (0.75, 1.21)	0.95 (0.74, 1.22)	0.79 (0.47, 1.33)	0.66 (0.37, 1.15)	0.99 (0.74, 1.31)	1.02 (0.76, 1.37)
4	0.93 (0.73, 1.18)	0.83 (0.64, 1.09)	0.56 (0.31, 1.00)	0.48 (0.25, 0.90)	1.02 (0.77, 1.36)	0.91 (0.67, 1.24)
5 = most	1.02 (0.80, 1.29)	0.98 (0.75, 1.27)	1.05 (0.64, 1.72)	1.06 (0.62, 1.78)	1.05 (0.79, 1.40)	0.97 (0.71, 1.32)
Rurality						
Urban	1.00	1.00	1.00	1.00	1.00	1.00
Rural	1.08 (0.89, 1.30)	1.06 (0.86, 1.31)	0.90 (0.57, 1.42)	0.90 (0.54, 1.49)	1.08 (0.86, 1.34)	1.06 (0.83, 1.36)
Ethnicity			-			-
White	1.00	1.00	1.00	1.00	1.00	1.00
Asian	1.11 (0.79, 1.56)	1.13 (0.80, 1.60)	1.15 (0.53, 2.48)	1.18 (0.54, 2.56)	1.13 (0.76, 1.69)	1.13 (0.75, 1.69)
Black	1.53 (0.99, 2.38)	1.61 (1.03, 2.52)	0.76 (0.19, 3.06)	0.75 (0.18, 3.09)	1.81 (1.13, 2.91)	1.88 (1.16, 3.05)

Mixed	0.35 (0.11, 1.10)	0.40 (0.13, 1.23)	-	-	0.49 (0.16, 1.52)	0.53 (0.17, 1.65)
Other	1.13 (0.67, 1.93)	1.19 (0.70, 2.03)	1.26 (0.40, 3.98)	1.31 (0.41, 4.15)	1.23 (0.67, 2.24)	1.27 (0.69, 2.32)

- *‡* = procedure level multi-variable logistic regression model including sex, age group, year, Charlson co-morbidity index, index of
- 261 multiple deprivation, rurality, and ethnicity; OR = odds ratio; CI = confidence interval;  $\dagger = At$  least one serious complication within
- 262 90 days, defined as either pulmonary embolism, myocardial infarction, stroke, infection requiring surgery, fasciotomy, neurovascular
- *injury, or death; \* = open or arthroscopic irrigation and lavage or debridement; = suppressed.*



266 *‡* = procedure level multi-variable logistic regression model including sex, age group, year, modified Charlson
 267 comorbidity index, index of multiple deprivation (quintile), rurality, and ethnicity

265

269 The patient factors associated with the risk of revision ACL reconstruction, contralateral ACL 270 reconstruction, and same side meniscal surgery is summarised in Table 4. Female patients were at 271 lower risk of revision ACL reconstruction (adjusted hazard ratio [HR] 0.81; 95% CI 0.74 to 0.89) 272 and subsequent meniscal surgery (adjusted HR 0.61; 95% CI 0.49 to 0.75), but not contralateral ACL 273 reconstruction (adjusted HR 1.06; 95% CI 0.95 to 1.18; Table 4). Older age groups (under 20-years vs. 20-39-years vs. 40-59-years vs 60-79-years), patients from rural regions or greater deprivation, 274 and patients of Asian and Black ethnicity were less likely to undergo revision ACL reconstruction 275 276 (Table 4). Patients of Asian ethnicity were also of lower risk of meniscus surgery but increased risk

277	of contralateral ACL reconstruction (Table 4). All three outcomes were slightly more common over
278	the duration of the study by year of treatment. Patients with a greater modified Charlson comorbidity
279	index were slightly more likely to undergo revision ACL reconstruction (adjusted HR 1.03 per unit;
280	95% CI 1.01 to 1.06) but not meniscal surgery (adjusted HR 0.99; 95% CI 0.93 to 1.05) or
281	contralateral reconstruction (adjusted HR 0.99; 95% CI 0.96 to 1.03; Table 4).
282	
283	The rate of mortality was lower in the ACL reconstruction cohort than reported in the general
284	population (risk ratio [RR] 0.09; 95% CI 0.05 to 0.14) (Table 5). For male patients (under the age of
285	80 years) undergoing ACL reconstruction, the risk of myocardial infarction was lower than in the
286	general population (RR 0.09; 95% CI 0.03 to 0.23). No myocardial infarction was identified for this
287	age-group in a female patient after ACL reconstruction. The rate of stroke (under the age of 75
288	years) was also lower in the ACL reconstruction cohort than the general population (RR 0.06; 95%
289	CI 0.01 to 0.23). In comparison, the risk of pulmonary embolism (RR 20.60; 95% CI 15.68 to 27.06)
290	and infection (RR 385.91; 95% CI 282.60 to 526.98) was elevated in comparison to general
291	population data. These data correspond to an estimated number needed to harm of 850 (95% CI 720-
292	1039) for one pulmonary embolism and 213 (95% CI 195-233) for one knee joint infection.
293	
294	TABLE 4: Unadjusted and adjusted hazard ratios for subsequent insilateral revision reconstruction.

contralateral ligament reconstruction, ipsilateral meniscal surgery

	Revisio	on ACLr	Subsequent Co	Subsequent Contralateral ACLr		Subsequent meniscal surgery	
	Crude HR	Adjusted HR	Crude HR	Adjusted HR	Crude HR	Adjusted HR	
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	
Sex							
Male	1.00	1.00	1.00	1.00	1.00	1.00	
Female	0.79 (0.73, 0.87)	0.81 (0.74, 0.89)	1.05 (0.95, 1.15)	1.06 (0.95, 1.18)	0.62 (0.50, 0.76)	0.61 (0.49, 0.75)	
Age group	·	·	·				
<20	1.78 (1.64, 1.93)	1.75 (1.61, 1.91)	2.28 (2.08, 2.51)	2.12 (1.92, 2.35)	2.22 (1.88, 2.61)	2.11 (1.78, 2.50)	
20-39	1.00	1.00	1.00	1.00	1.00	1.00	
40-59	0.52 (0.46, 0.59)	0.51 (0.44, 0.58)	0.44 (0.37, 0.52)	0.42 (0.35, 0.51)	0.36 (0.26, 0.50)	0.34 (0.24, 0.48)	
60-79	0.23 (0.07, 0.70)	0.15 (0.04, 0.61)	0.23 (0.06, 0.93)	0.13 (0.02, 0.89)	-	-	

80+	-	-	-	-	-	-
Year						
Per year	1.03 (1.02, 1.04)	1.01 (1.00, 1.02)	1.07 (1.06, 1.09)	1.06 (1.04, 1.07)	1.14 (1.11, 1.17)	1.12 (1.09, 1.15)
Modified Cha	Modified Charlson comorbidity index					
Per unit	1.03 (1.01, 1.05)	1.03 (1.01, 1.06)	1.00 (0.97, 1.04)	0.99 (0.96, 1.03)	1.01 (0.95, 1.07)	0.99 (0.93, 1.05)
Index of multiple deprivation (quintile)						
1 = least	1.00	1.00	1.00	1.00	1.00	1.00
2	0.87 (0.78, 0.96)	0.88 (0.79, 0.97)	0.93 (0.82, 1.06)	0.95 (0.82, 1.09)	0.98 (0.79, 1.20)	0.94 (0.75, 1.16)
3	0.79 (0.71, 0.88)	0.80 (0.72, 0.89)	1.01 (0.89, 1.15)	1.00 (0.87, 1.15)	0.82 (0.66, 1.03)	0.83 (0.66, 1.04)
4	0.78 (0.70, 0.87)	0.74 (0.66, 0.82)	0.99 (0.87, 1.13)	0.96 (0.83, 1.11)	0.79 (0.63, 0.99)	0.75 (0.60, 0.95)
5 = most	0.68 (0.61, 0.77)	0.64 (0.56, 0.72)	1.03 (0.91, 1.18)	0.96 (0.83, 1.11)	0.58 (0.45, 0.74)	0.52 (0.40, 0.69)
Rurality						
Urban	1.00	1.00	1.00	1.00	1.00	1.00
Rural	0.83 (0.75, 0.91)	0.76 (0.69, 0.84)	1.02 (0.92, 1.13)	0.98 (0.87, 1.11)	0.98 (0.81, 1.17)	0.89 (0.73, 1.08)
Ethnicity						
White	1.00	1.00	1.00	1.00	1.00	1.00
Asian	0.75 (0.62, 0.90)	0.73 (0.61, 0.89)	1.34 (1.11, 1.61)	1.31 (1.09, 1.59)	0.59 (0.37, 0.91)	0.58 (0.37, 0.91)
Black	0.72 (0.55, 0.95)	0.74 (0.56, 0.97)	1.05 (0.78, 1.42)	1.00 (0.74, 1.35)	0.69 (0.38, 1.25)	0.73 (0.40, 1.34)
Mixed	1.15 (0.85, 1.55)	1.09 (0.81, 1.46)	1.26 (0.87, 1.84)	1.09 (0.75, 1.59)	1.17 (0.63, 2.19)	1.05 (0.56, 1.97)
Other	0.48 (0.33, 0.69)	0.50 (0.34, 0.72)	1.04 (0.75, 1.45)	1.07 (0.77, 1.48)	0.46 (0.21, 1.03)	0.49 (0.22, 1.09)

*‡* = procedure level Cox proportional hazards model including sex, age group, year, Charlson co-morbidity index, index of multiple

299 deprivation, rurality, and ethnicity. HR = hazard ratio; CI = confidence interval; ACLr = anterior cruciate ligament reconstruction; -

300 = suppressed.

# 304 TABLE 5: 90-day adverse event rates in study cohort versus age and/or sex matched general population

## 305 data

# 306

	General population risk % (95%	Study cohort risk % (95% CI)	Risk ratio (95% CI)
	CI) [publication reference]		
Mortality			
Overall:	0.158% (0.157, 0.159) 10 *	0.013% (0.007, 0.023)	0.09 (0.05, 0.14)
Age < 20 years:	0.007% (0.007, 0.008) 10 *	0.007% (0.000, 0.036)	0.89 (0.12, 6.30)
Age 20 - 39 years:	0.011% (0.011, 0.012) 10 *	0.010% (0.004, 0.020)	0.84 (0.40, 1.77)
Age 40 - 59 years:	0.043% (0.042, 0.044) 10 *	0.031% (0.010, 0.073)	0.73 (0.30, 1.75)
Age 60 - 79 years:	0.233% (0.230, 0.236) 10 *	0.000% (0.000, 0.774)	-
Age 80 + years:	2.043% (2.026, 2.060) <sup>10</sup> *	4.348% (0.110, 21.949)	2.08 (0.31, 14.18)
Myocardial infarction			
Men (age < 80):	0.058% (0.049, 0.067) 38	0.005% (0.001, 0.013)	0.09 (0.03, 0.23)
Women (age < 80):	0.028% (0.022, 0.035) 38	0.000% (0.000, 0.016)	-
Pulmonary embolism			
Overall:	0.006% (0.005, 0.007) <sup>36</sup>	0.124% (0.103, 0.147)	20.60 (15.68, 27.06)
Stroke			
Age < 75 years:	0.034% (0.030, 0.039) 12	0.002% (0.000, 0.007)	0.06 (0.01, 0.23)
Septic arthritis (native	knee joint infection)		-
Overall:	0.001% (0.001, 0.002) 17 ‡	0.474% (0.433, 0.517)	385.91 (282.60, 526.98)

307

309 \*= Office for National Statistics population level data for England (2016, excluding death due to cancer);

310  $\ddagger = excluding introgenic causes.$ 

<sup>308 - =</sup> *suppressed;* 

312 **DISCUSSION** 

#### 313

314 Principal findings

315 Our study of 104 255 procedures shows that serious adverse events occur rarely following ACL 316 reconstruction and that the risk of serious complications has fallen slightly over time. Most medical 317 adverse events occur less frequently following ACL reconstruction than in the general population 318 which is likely a healthy-cohort observation, however there is an important attributable risk of a pulmonary embolism and infection. For every 850 ACL reconstructions performed, one pulmonary 319 embolism and four knee infections could occur and be attributed to the procedure. Around 3.2% of 320 321 patients undergo revision ACL reconstruction and 2.9% contralateral ACL reconstruction within five-years. These findings will be crucial to informing patients and clinicians when deciding whether 322 to proceed with elective ACL reconstruction. The recognised benefits of the procedure can now be 323 324 interpreted in the context of the associated potential risks.

325

## 326 <u>Comparison with previous studies</u>

Despite the number of ACL reconstruction procedures performed worldwide,<sup>2,5,26</sup> the adverse outcomes attributable to undergoing the procedure have previously been poorly defined. Several studies have reported adverse events following "knee arthroscopy" but few have reported data specifically for ACL reconstruction in comparison to more commonly performed purely arthroscopic, procedures such as arthroscopic partial meniscectomy.<sup>4,13,21,22,24,32–34,37</sup> In comparison, anterior cruciate ligament reconstruction is a more major intervention, associated with greater operative time and usually both open and arthroscopic incisions and techniques.<sup>31</sup>

334

335 In our study, only pulmonary embolism and infection were found to occur at a greater rate than

336 observed in comparative general population data. These findings are similar to those reported

- recently for a cohort of 699 965 arthroscopic partial meniscectomy procedures.<sup>1</sup> In this
- meniscectomy cohort, serious complications occurred in 0.32% (95% CI 0.30 to 0.33) in comparison

339 to 0.65% (95% CI 0.60 to 0.70) following ACL reconstruction using the same definitions. This 340 difference in the serious complication rate was driven in part by a higher reoperation rate for 341 infection following ACL reconstruction at 0.47% (95% CI 0.43 to 0.52) in comparison to 0.14% 342 (95% CI 0.13 to 0.14) following arthroscopic partial meniscectomy.<sup>1</sup> The infection rate identified in 343 our study was similar but statistically more precise with an estimated deep infection rate of 0.43% (58/13401; 95% CI 0.32 to 0.56) ACL reconstruction cases reported in a systematic review of level 2 344 345 studies in 2017.<sup>4</sup> It is, however, higher than a rate of 0.14% (7/4933; 95% CI 0.05 to 0.29) reported in a study of the American College of Surgeons National Surgical Quality Improvement Program 346 (ACS NSQIP) database.<sup>9</sup> With comparison to general population data, the estimated number needed 347 348 to harm for infection was 213 for our ACL reconstruction cohort versus 749 for the arthroscopic 349 partial meniscectomy cohort.1

350

The rate of pulmonary embolism within 90-days was greater in our ACL reconstruction cohort at 351 0.12% (95% CI 0.10 to 0.15) in comparison to 0.08% (95% CI 0.07 to 0.09) in the recent 352 arthroscopic partial meniscectomy cohort.<sup>1</sup> No cases of fatal pulmonary embolism were identified 353 354 following ACL reconstruction. The pulmonary embolism rate was comparable but statistically much more precise than the estimated rate of pulmonary embolism reported in a systematic review of 355 356 forty-seven ACL reconstruction studies published in 2016, which reported a mean pulmonary embolism rate of 0.14% but with wide confidence intervals (1/704; 95% CI 0.00 to 0.79).<sup>22</sup> The rate 357 is also the same as another 2016 study of 4933 patients reporting a PE rate of 0.12% within 30-days 358 (6/4933).<sup>9</sup> With comparison to general population data, the number needed to harm for pulmonary 359 embolism was estimated to be 850 for ACL reconstruction in comparison to 1390 for arthroscopic 360 361 partial meniscectomy.<sup>1</sup>

362

363 Prescribing data is unavailable in this database and therefore the type and duration of any antibiotic 364 or venous thromboembolic (VTE) prophylaxis given to the patients in this study is unknown and it is 365 likely that local practice varied. Previous work suggested that while antibiotic prophylaxis is routine in most countries, VTE prophylaxis rates vary from around 17% Norway, 51% in the United States,
to 79% in Denmark.<sup>18,23</sup> The findings in this study may support further investigation and
consideration of routine VTE prophylaxis in this population.

369

370 Other direct surgical complications such as neurovascular injury and fasciotomy could not be 371 compared to general population data. Both neurovascular injury and fasciotomy procedures were identified rarely following ACL reconstruction, at 0.02% in both cases. It must be noted, however, 372 373 that these rates are approximately 5-10 times greater than reported following arthroscopic partial meniscectomy.<sup>1</sup> The greater risk of these complications, infection, and pulmonary embolism, 374 375 associated with ACL reconstruction in comparison to arthroscopic partial meniscectomy is unsurprising given the more invasive nature of ACL reconstruction, with additional surgical 376 incisions and more prolonged operative time.<sup>31</sup> 377

378

Regarding reoperation rates, the largest previous study published in 2016 reported an ACL revision rate of 3.6% (587/16336; 95% CI 3.31 to 3.89), utilising US military health record data.<sup>32</sup> Our study reports a very similar rate of revision at 3.22% and adds importantly to these data, reporting contralateral ACL reconstruction in 2.86% and same side meniscal surgery in 0.63% within fiveyears. The risk of revision ACL reconstruction was considerably greater in younger age groups, although it unknown if this reflects differences in injury rates or differences in propensity to reoperate following injury.

386

387 It is interesting that the risk of revision ACL reconstruction in the same knee was similar to the risk 388 of contralateral ACL reconstruction, which suggests that both the reconstructed ligament and the 389 native opposite knee ligament are at comparable risk of rupture following an ACL reconstruction. A 390 systematic review of nine studies and a smaller number of patients previously reported an ipsilateral 391 graft re-rupture rate of 7.9% (211/2682) but a higher 12.5% (335/2682) risk of contralateral ACL 392 injury.<sup>24</sup> Rates of subsequent meniscal surgery after ACL injury have rarely been reported. Frobell

et. al. reported a 9.7% (6/62; 95% CI 3.6 to 19.9) following ACL reconstruction and up to 49.2%
(29/59; 95% CI 35.9 to 62.5) following a non-operative treatment strategy. A much lower rate of
subsequent meniscal surgery was observed in our population at 0.63% (95% CI 0.56 to 0.70) which
may reflect higher thresholds for subsequent intervention or lower symptomatic injury rates.

398 Our study found revision reconstruction rates to be lower in women. This finding is similar to a 399 recent systematic review of smaller studies which reported lower rates of ipsilateral graft rupture in women.<sup>27</sup> This review also found women had a higher rate of contralateral knee injury however in 400 our study we found no difference in contralateral knee reconstruction rates in women versus men. 401 402 Subsequent meniscal surgery rates were also lower in women than men. Our study provides clear reference data for reconstruction rates in men and women and further investigation into the 403 physiological, anatomical, and biomechanical factors that underlie these differences is warranted, 404 405 with specific focus on preventative interventions. These findings will be crucial to the education of 406 patients following ACL injury and reconstruction and inform collaboration between patients, 407 physiotherapists, and clinicians in optimising current and future rehabilitation strategies.

408

### 409 Strengths and limitations

Our study is strengthened by the inclusion of 104 255 ACL reconstruction cases over a twenty-year 410 period, utilising data from the complete national health database for England, UK. To our 411 412 knowledge, this is by far the largest reported series of ACL reconstruction cases and the largest to 413 report adverse outcomes. Patients undergoing bilateral surgery (within 6 months), multiple ligament reconstruction, ACL repair, synthetic graft procedures, or articular cartilage surgery were excluded. 414 415 Patients undergoing concurrent meniscal procedures were, however, included as these procedures 416 were common (approximately 28%) and therefore including these cases makes the cohort more 417 representative of normal practice. Our study is also the most comprehensive evaluation of adverse 418 outcomes, including the broad range of surgical and medical complications that may occur and, 419 where possible, risk has been compared to age-sex matched general population data. The comparison

- to general population data is relative crude but together with adverse outcome data following
  arthroscopic partial meniscectomy extracted from the same database, provides for the first time an
  important estimate of the attributable risk associated with ACL reconstruction.
- 423

424 HES data includes diagnosis and intervention data from admitted hospital care episodes in the 425 national health service, England, and is collected routinely for hospital reimbursement, audit and 426 research purposes. Although HES comprehensively records diagnosis and procedural data for patients admitted to hospital, there are some limitations. Although our data included a patient-427 specific modified Charlson comorbidity index, there are some important patient specific factors such 428 429 as body mass index and smoking status that are not recorded in HES and are likely to impact upon risk. Regarding the accuracy of data coding in the database, the Charlson comorbidity index as 430 calculated from HES diagnosis fields and records of serious vascular complications have been 431 validated against primary care data.<sup>8,40</sup> Some patient variables such as ethnicity, however, may be 432 433 less reliably coded. It is also important to note that the OPCS-4 codes used to identify ACL reconstruction procedures for our patient cohort will have captured some posterior cruciate ligament 434 reconstruction procedures. This is inevitable given the nature of the codes used for this procedure but 435 the proportion of the posterior cruciate ligament reconstruction procedures performed is very small 436 437 in comparison to ACL reconstruction and therefore we believe these procedures are unlikely to have materially altered our findings.<sup>3</sup> The first ACL reconstruction per patient, per knee, was considered 438 439 the primary procedure and revision procedures identified as any subsequent ACL reconstruction. 440 Any primary procedure undertaken prior to 1<sup>st</sup> April 1997, however, would be not be identified and 441 therefore it is possible a small number of revision procedures could have been included in our cohort 442 as no "revision" code is available. From HES data we are also unable to determine the impact from 443 operative factors, such as reconstruction technique and choice of graft on outcome as these operative 444 techniques are not recorded.

446 Diagnoses from primary care or the outpatient department are not available in the HES inpatient 447 dataset unless these diagnoses were associated with a later hospital admission for care or surgery. 448 This means, for example, that the reported revision ACL reconstruction and contralateral ACL 449 reconstruction rates in our study will be lower than the true ACL injury rates in the population. 450 Similarly, soft tissue infections managed non-operatively will not have been recorded. Another 451 limitation of the HES database is that laboratory and radiological data is not recorded. Therefore, 452 whilst cases of knee open or arthroscopic irrigation and lavage or debridement with an associated 'haemarthrosis' diagnosis code were not recorded as infections, from the remaining lavage and 453 debridement procedures we cannot distinguish procedures performed for a laboratory confirmed 454 455 infection from those with a suspected infection. The clinical implications in each case may be quite different and an important limitation of this observational HES data. It must also be considered that 456 some patients may have undergone their primary ACL reconstruction in the national health service 457 458 but subsequent care in the private health sector. This is unlikely to have affected the record of 459 adverse events within 90-days, as patients are highly likely to have returned to a national health 460 hospital in these cases. In the longer term, however, some patients may have chosen to have revision 461 ACL reconstruction or contralateral ACL reconstruction in the private health sector and would not be 462 captured and this must be considered when interpreting our long-term reoperation data. Minor adverse outcomes that may have been managed in primary care would also not be captured. Our 463 findings are, however, by far the most comprehensive to date regarding the true risk of serious 464 complications associated with undergoing ACL reconstruction and, we believe, should be broadly 465 466 generalisable to ACL reconstruction practice in developed countries, worldwide.

467

468 <u>Conclusion</u>

469 Whilst the risk of adverse events following ACL reconstruction is greater than following

470 arthroscopic partial meniscectomy, the overall risk is still low and most medical complications

- 471 (myocardial infarction, stroke, death) occur less frequently following ACL reconstruction than in the
- 472 general population. Nevertheless, rare but serious complications including pulmonary embolism,

- 473 infection, fasciotomy and neurovascular injury may by provoked by undergoing ACL reconstruction.
- 474 Same side and contralateral knee ACL reconstruction was performed in 3.2% and 2.9% of cases
- 475 within 5-years of primary ACL reconstruction respectively. Our findings will be crucial to informing
- 476 patients considering the relative risks and benefits of undergoing early ACL reconstruction in
- 477 comparison to the emerging treatment strategy of rehabilitation and optional delayed ACL
- 478 reconstruction. Further work is required to optimise not only the primary treatment selection but also
- 479 strategies to reduce reinjury rates.
- 480

481	REF	<b>ER</b>	EN	CES
-----	-----	-----------	----	-----

482		
483	1.	Abram SGF, Judge A, Beard DJ, Price AJ. Adverse outcomes after arthroscopic partial
484		meniscectomy: a study of 700 000 procedures in the national Hospital Episode Statistics
485		database for England. Lancet. 2018;392(10160):2194-2202. doi:10.1016/S0140-
486		6736(18)31771-9.
487	2.	Abram SGF, Price AJ, Judge A, Beard DJ. Anterior cruciate ligament (ACL) reconstruction
488		and meniscal repair rates have both increased in the past 20 years in England: hospital
489		statistics from 1997 to 2017. Br J Sports Med. January 2019:bjsports-2018-100195.
490		doi:10.1136/bjsports-2018-100195.
491	3.	Årøen A, Sivertsen EA, Owesen C, Engebretsen L, Granan LP. An isolated rupture of the
492		posterior cruciate ligament results in reduced preoperative knee function in comparison with
493		an anterior cruciate ligament injury. Knee Surgery, Sport Traumatol Arthrosc.
494		2013;21(5):1017-1022. doi:10.1007/s00167-012-2132-1.
495	4.	Bansal A, Lamplot JD, Vandenberg JT, Brophy RH. Meta-analysis of the Risk of Infections
496		After Anterior Cruciate Ligament Reconstruction by Graft Type. Am J Sports Med.
497		2017:036354651771445. doi:10.1177/0363546517714450.
498	5.	Buller LT, Best MJ, Baraga MG, Kaplan LD. Trends in Anterior Cruciate Ligament
499		Reconstruction in the United States. Orthop J Sport Med. 2015;3(1):232596711456366.
500		doi:10.1177/2325967114563664.
501	6.	Chan SW, Tulloch E, Cooper ES, Smith A, Wojcik W, Norman JE. Montgomery and
502		informed consent: where are we now? BMJ. 2017;2224(May):j2224. doi:10.1136/bmj.j2224.
503	7.	Charlson ME, Pompei P, Ales KL, MacKenzie R. A new method of classifying prognostic in
504		longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. doi:0021-
505		9681/87.
506	8.	Crooks CJ, West J, Card TR. A comparison of the recording of comorbidity in primary and
507		secondary care by using the Charlson Index to predict short-term and long-term survival in a

- 508 routine linked data cohort. *BMJ Open*. 2015;5(6):1-9. doi:10.1136/bmjopen-2015-007974.
- 509 9. Cvetanovich GL, Chalmers PN, Verma NN, Cole BJ, Bach BR. Risk Factors for Short-term
- 510 Complications of Anterior Cruciate Ligament Reconstruction in the United States. *Am J*

511 Sports Med. 2016;44(3):618-624. doi:10.1177/0363546515622414.

- 512 10. Deaths Office for National Statistics.; 2018.
- https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  Accessed January 16, 2018.
- 515 11. Evans S, Shaginaw J, Bartolozzi A. ACL reconstruction it's all about timing. *Int J Sports*516 *Phys Ther.* 2014;9(2):268-273.
- 517 http://www.ncbi.nlm.nih.gov/pubmed/24790787%5Cnhttp://www.pubmedcentral.nih.gov/arti
- 518 clerender.fcgi?artid=PMC4004131%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi
  519 ?artid=4004131&tool=pmcentrez&rendertype=abstract.
- 520 12. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke
- 521 during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet (London,*
- 522 *England*). 2014;383(9913):245-254. http://www.ncbi.nlm.nih.gov/pubmed/24449944.

523 Accessed January 16, 2018.

- 524 13. Figueiredo S, Sa Castelo L, Pereira AD, Machado L, Silva JA, Sa A. Use of MRI by
- radiologists and orthopaedic surgeons to detect intra-articular injuries of the knee. *Rev Bras Ortop.* 2018;53(1):28-32. doi:10.1016/j.rbo.2016.12.003.
- 527 14. Filbay SR, Roos EM, Frobell RB, Roemer F, Ranstam J, Lohmander LS. Delaying ACL

528 reconstruction and treating with exercise therapy alone may alter prognostic factors for 5-year

- 529 outcome: an exploratory analysis of the KANON trial. Br J Sports Med. 2017;51(22):1622-
- 530 1629. doi:10.1136/bjsports-2016-097124.
- 531 15. Frank CB, Jackson DW. The science of reconstruction of the anterior cruciate ligament. J

532 Bone Joint Surg Am. 1997;79(10):1556-1576. http://jbjs.org/content/79/10/1556.abstract.

- 533 16. Frobell RB, Roos EM, Roos HP, Ranstam J, Lohmander LS. A randomized trial of treatment
- for acute anterior cruciate ligament tears. *N Engl J Med*. 2010;363(4):331-342.

- 535 doi:10.1056/NEJMoa0907797.
- 536 17. Geirsson ÁJ, Statkevicius S, Víkingsson A. Septic arthritis in Iceland 1990-2002: Increasing
  537 incidence due to iatrogenic infections. *Ann Rheum Dis*. 2008;67(5):638-643.

538 doi:10.1136/ard.2007.077131.

- 539 18. Granan LP, Forssblad M, Lind M, Engebretsen L. The scandinavian ACL registries 2004-
- 540 2007: Baseline epidemiology. *Acta Orthop*. 2009;80(5):563-567.

541 doi:10.3109/17453670903350107.

- Hagino T, Ochiai S, Senga S, et al. Meniscal tears associated with anterior cruciate ligament
  injury. *Arch Orthop Trauma Surg.* 2015;135(12):1701-1706. doi:10.1007/s00402-015-2309-4.
- 544 20. HSCIC. Summary Hospital-Level Mortality Indicator (SHMI). Indicator Specification.

545 *Version 1.25.* Vol v1.25.; 2017. https://www.digital.nhs.uk/SHMI.

- 546 21. Jameson SS, Dowen D, James P, Serrano-Pedraza I, Reed MR, Deehan D. Complications
- 547 following anterior cruciate ligament reconstruction in the English NHS. *Knee*. 2012;19(1):14-

548 19. doi:10.1016/j.knee.2010.11.011.

- 549 22. Janssen RPA, Reijman M, Janssen DM, van Mourik JBA. Arterial complications, venous
- thromboembolism and deep venous thrombosis prophylaxis after anterior cruciate ligament

551 reconstruction: A systematic review. *World J Orthop*. 2016;7(9):604.

- 552 doi:10.5312/wjo.v7.i9.604.
- 553 23. Keller RA, Moutzouros V, Dines JS, Bush-Joseph CA, Limpisvasti O. Deep Venous
- 554 Thrombosis Prophylaxis in Anterior Cruciate Ligament Reconstructive Surgery: What Is the
- 555 Current State of Practice? *Sports Health*. 2018;10(2):156-159.
- 556 doi:10.1177/1941738117730576.
- 557 24. Magnussen RA, Meschbach NT, Kaeding CC, Wright RW, Spindler KP. ACL Graft and
- 558 Contralateral ACL Tear Risk within Ten Years Following Reconstruction. *JBJS Rev.*
- 559 2015;3(1):1. doi:10.2106/JBJS.RVW.N.00052.
- 560 25. Monk AP, Davies LJ, Hopewell S, Harris K, Beard DJ, Price AJ. Surgical versus conservative
- 561 interventions for treating anterior cruciate ligament injuries. *Cochrane Database Syst Rev.*

- 562 April 2016. doi:10.1002/14651858.CD011166.pub2.
- 563 26. Moses B, Orchard J, Orchard J. Systematic review: Annual incidence of ACL injury and
- surgery in various populations. *Res Sport Med.* 2012;20(3-4):157-179.

565 doi:10.1080/15438627.2012.680633.

- 566 27. Nawasreh Z, Adams G, Pryzbylkowski O, Logerstedt D. INFLUENCE OF PATIENT
- 567 DEMOGRAPHICS AND GRAFT TYPES ON ACL SECOND INJURY RATES IN
- 568 IPSILATERAL VERSUS CONTRALATERAL KNEES: A SYSTEMATIC REVIEW AND
- 569 META-ANALYSIS. Int J Sports Phys Ther. 2018;13(4):561-574.
- 570 http://www.ncbi.nlm.nih.gov/pubmed/30140550. Accessed October 17, 2018.
- 571 28. NHS Digital. Hospital Episode Statistics. http://content.digital.nhs.uk/hes. Accessed
  572 December 4, 2017.
- 573 29. NHS Digital. National Clinical Coding Standards: OPCS-4 (2017). Stationery Office; 2017.
- Noble M, Wright} G, Smith G, Dibben} C. Measuring multiple deprivation at the small-area
  level. *Environ Plan A*. 2006;38:169-185. doi:10.1068/a37168.
- 576 31. Paschos NK, Howell SM. Anterior cruciate ligament reconstruction: principles of treatment.
   577 *EFORT Open Rev.* 2016;1(11):398-408. doi:10.1302/2058-5241.1.160032.
- 578 32. Pullen WM, Bryant B, Gaskill T, Sicignano N, Evans AM, DeMaio M. Predictors of Revision
- 579 Surgery After Anterior Cruciate Ligament Reconstruction. Am J Sports Med.
- 580 2016;44(12):3140-3145. doi:10.1177/0363546516660062.
- 581 33. Ryan J, Magnussen RA, Cox CL, Hurbanek JG, Flanigan DC, Kaeding CC. ACL
- 582 reconstruction: Do outcomes differ by sex? A Systematic Review. *J Bone Jt Surg Ser A*.
- 583 2014;96(6):507-512. doi:10.2106/JBJS.M.00299.
- 584 34. Sanders TL, Pareek A, Hewett TE, et al. Long-term rate of graft failure after ACL
- 585 reconstruction: a geographic population cohort analysis. *Knee Surgery, Sport Traumatol*
- 586 *Arthrosc.* 2017;25(1):222-228. doi:10.1007/s00167-016-4275-y.
- 587 35. Sherman MF, Lieber L, Bonamo JR, Podesta L, Reiter I. The long-term followup of primary
- 588 cruciate ligament repair. Am J Sports Med. 1991;19(3):243-255.

- 589 36. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of
- 590 patients with venous thromboembolism. The Worcester VTE study. *J Thromb Thrombolysis*.

591 2009;28(4):401-409. doi:10.1007/s11239-009-0378-3.

- 59237.Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee:
- 593 systematic review and meta-analysis of benefits and harms. *Bmj*. 2015;350(jun16 3):h2747-
- 594 h2747. doi:10.1136/bmj.h2747.
- 595 38. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA. Coronary event and case
- 596 fatality rates in an English population: results of the Oxford myocardial infarction incidence
- 597 study. The Oxford Myocardial Infarction Incidence Study Group. *Heart*. 1998;80(1):40-44.
- 598 doi:10.1136/HRT.80.1.40.
- World Health Organisation. International Statistical Classification of Diseases and Related
  Health Problems 10th Revision. WHO.
- http://apps.who.int/classifications/icd10/browse/2016/en. Published 2016. Accessed January
  12, 2018.
- Wright FL, Green J, Canoy D, Cairns BJ, Balkwill A, Beral V. Vascular disease in women:
  comparison of diagnoses in hospital episode statistics and general practice records in England. *BMC Med Res Methodol.* 2012;12(1):161. doi:10.1186/1471-2288-12-161.
- 41. Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and
  sources of information for Charlson comorbidity adjustment in Medicare claims. *Med Care*.
  1999;37(11):1128-1139. http://www.ncbi.nlm.nih.gov/pubmed/10549615.
- 609